Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype

On-treatment decline of serum hepatitis B surface antigen (HBsAg) may reflect the immunomodulatory effect of pegylated interferon (PEG-IFN) for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB). We compared HBsAg decline across HBV genotypes between combined responders (HBeAg loss and...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral therapy 2012, Vol.17 (1), p.9-17
Main Authors: SONNEVELD, Milan J, RIJCKBORST, Vincent, LA JANSSEN, Harry, CAKALOGLU, Yilmaz, SIMON, Krzysztof, HEATHCOTE, E. Jenny, TABAK, Fehmi, MACH, Tomasz, AB BOUCHER, Charles, HANSEN, Bettina E, ZEUZEM, Stefan
Format: Article
Language:English
Subjects:
Adult
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Antiviral Agents - administration & dosage
Antiviral Agents - therapeutic use
Biological and medical sciences
Biomarkers, Pharmacological - blood
DNA, Viral - blood
Female
Follow-Up Studies
Genotype
Hepatitis B e Antigens - blood
Hepatitis B Surface Antigens - blood
Hepatitis B virus - genetics
Hepatitis B, Chronic - blood
Hepatitis B, Chronic - drug therapy
Hepatitis B, Chronic - virology
Human viral diseases
Humans
Infectious diseases
Interferon-alpha - administration & dosage
Interferon-alpha - therapeutic use
Lamivudine - administration & dosage
Lamivudine - therapeutic use
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Polyethylene Glycols - administration & dosage
Polyethylene Glycols - therapeutic use
Recombinant Proteins - administration & dosage
Recombinant Proteins - therapeutic use
Treatment Outcome
Viral diseases
Viral hepatitis
Viral Load - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:On-treatment decline of serum hepatitis B surface antigen (HBsAg) may reflect the immunomodulatory effect of pegylated interferon (PEG-IFN) for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB). We compared HBsAg decline across HBV genotypes between combined responders (HBeAg loss and HBV DNA10,000 copies/ml) and non-responders. HBsAg was measured at baseline, on-treatment and 6 months post-treatment in 221 HBeAg-positive CHB patients treated with PEG-IFN with or without lamivudine for 52 weeks, and in a representative subgroup of 142 patients at long-term follow-up (LTFU; mean 3.0 years). On-treatment HBsAg decline significantly varied according to HBV genotype (A and B more than C and D; P
ISSN:1359-6535
2040-2058
DOI:10.3851/IMP1887